Caffeic acid phenethyl ester (Synonyms: 咖啡酸苯乙酯)

目录号: HY-N0274 纯度: 99.96%: FAQs
Data Sheet SDS COA 产品使用指南技术支持

Caffeic acid phenethyl ester 是一种 NF-κB 抑制剂。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Caffeic acid phenethyl ester Chemical Structure

CAS No. : 104594-70-9

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥500	In-stock
1 mg	￥225	In-stock
5 mg	￥450	In-stock
10 mg	￥540	In-stock
25 mg	￥750	In-stock
50 mg	￥900	In-stock
100 mg	￥1080	In-stock
200 mg	￥1300	In-stock
500 mg		询价
1 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Caffeic acid phenethyl ester:

Caffeic acid In-stock

MCE 顾客使用本产品发表的 12 篇科研文献

: Caffeic acid phenethyl ester purchased from MCE. Usage Cited in: Mediat Inflamm. 2020 Jun 6;2020:4321912. [Abstract]; Immunofluorescence results show that the nucleus of agonist-CD137 group clearly changed from red to yellow, indicating NF-κB translocation has occurred in these cells. However, pretreatment with inhibitor of Caffeic acid phenethyl ester (CAPE) blocks the effect of CD137 signaling on the nuclear translocation of NF-κB .

: Caffeic acid phenethyl ester purchased from MCE. Usage Cited in: Mediat Inflamm. 2020 Jun 6;2020:4321912. [Abstract]; Western blot analysis reveals that CD137 signaling broadly increased the expression of NF-κB in the nucleus of HUVECs but decreased upon CAPE treatment.

Caffeic acid phenethyl ester 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 NF-κB 亚型特异性产品:

查看所有亚型

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

Caffeic acid phenethyl ester is a NF-κB inhibitor.

IC₅₀ & Target^[1]

NF-κB

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
786-0	IC₅₀	26.8 μM Compound: 2; CAPE	Cytotoxicity against VHL-deficient human 786-0 cells assessed as reduction in cell viability incubated for 4 days by XTT assay Cytotoxicity against VHL-deficient human 786-0 cells assessed as reduction in cell viability incubated for 4 days by XTT assay	[PMID: 31260889]
786-0	IC₅₀	43.8 μM Compound: 2; CAPE	Cytotoxicity against VHL-positive human 786-0 cells assessed as reduction in cell viability incubated for 4 days by XTT assay Cytotoxicity against VHL-positive human 786-0 cells assessed as reduction in cell viability incubated for 4 days by XTT assay	[PMID: 31260889]
A2780	EC₅₀	3.5 μM Compound: 17; CAPE	Cytotoxicity against human A2780 cells measured after 96 hrs by SRB assay Cytotoxicity against human A2780 cells measured after 96 hrs by SRB assay	[PMID: 31158743]
A549	IC₅₀	26.8 μM Compound: 1, CAPE	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 20673727]
A549	EC₅₀	27.9 μM Compound: 14	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 12027739]
A549	IC₅₀	80 μM Compound: 2; CAPE	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 33210536]
A549	IC₅₀	83.6 μM Compound: III-19	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 18952420]
A549	IC₅₀	9.72 μM Compound: CAPE	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 26638042]
B16-BL6	EC₅₀	6.79 μM Compound: 14	Antiproliferative activity against mouse B16-BL6 cells after 72 hrs by MTT assay Antiproliferative activity against mouse B16-BL6 cells after 72 hrs by MTT assay	[PMID: 12027739]
B16-F10	IC₅₀	10.68 μM Compound: CAPE	Antiproliferative activity against mouse B16F10 cells after 72 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells after 72 hrs by MTT assay	[PMID: 26638042]
Bel-7402	IC₅₀	5.5 μM Compound: III-19	Cytotoxicity against human Bel7402 cells by MTT assay Cytotoxicity against human Bel7402 cells by MTT assay	[PMID: 18952420]
BEL-7404 tumor cell line	IC₅₀	14.5 μM Compound: 1, CAPE	Cytotoxicity against human Bel7404 cells after 72 hrs by MTT assay Cytotoxicity against human Bel7404 cells after 72 hrs by MTT assay	[PMID: 20673727]
BeWo	IC₅₀	2.96 μM Compound: I-18	Antitumor activity against human Bewo cells assessed as inhibition of cell growth by MTT assay Antitumor activity against human Bewo cells assessed as inhibition of cell growth by MTT assay	[PMID: 25160837]
BGC-823	IC₅₀	19.3 μM Compound: 1, CAPE	Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay	[PMID: 20673727]
BV-2	IC₅₀	6.4 μM Compound: 1, CAPE	Inhibition of nitric oxide production in LPS-stimulated mouse BV2 cells treated 3 hrs before LPS addition measured after 24 hrs by Griess assay Inhibition of nitric oxide production in LPS-stimulated mouse BV2 cells treated 3 hrs before LPS addition measured after 24 hrs by Griess assay	[PMID: 23870700]
BV-2	IC₅₀	6.4 μM Compound: 1, CAPE	Antineuroinflammatory activity in mouse BV2 cells assessed as reduction of LPS-induced nitric oxide production treated 3 hrs before LPS addition measured after 24 hrs by Griess assay Antineuroinflammatory activity in mouse BV2 cells assessed as reduction of LPS-induced nitric oxide production treated 3 hrs before LPS addition measured after 24 hrs by Griess assay	[PMID: 23726032]
BV-2	IC₅₀	6.4 μM Compound: 1, CAPE	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 3 hrs followed by LPS challenge measured after 24 hrs by Griess assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 3 hrs followed by LPS challenge measured after 24 hrs by Griess assay	[PMID: 24697335]
Caco-2	IC₅₀	11.35 μM Compound: CAPE	Antiproliferative activity against human Caco2 cells after 72 hrs by MTT assay Antiproliferative activity against human Caco2 cells after 72 hrs by MTT assay	[PMID: 26638042]
CNE	IC₅₀	54 μM Compound: 1, CAPE	Cytotoxicity against human CNE cells after 72 hrs by MTT assay Cytotoxicity against human CNE cells after 72 hrs by MTT assay	[PMID: 20673727]
DU-145	IC₅₀	16 μM Compound: CAPE	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 27979593]
ECa-109 cell line	IC₅₀	42.6 μM Compound: 1, CAPE	Cytotoxicity against human ECA109 cells after 72 hrs by MTT assay Cytotoxicity against human ECA109 cells after 72 hrs by MTT assay	[PMID: 20673727]
ECa-109 cell line	IC₅₀	47.5 μM Compound: CAPE	Antiproliferative activity against human ECA109 cells after 48 hrs by MTT assay Antiproliferative activity against human ECA109 cells after 48 hrs by MTT assay	[PMID: 27979593]
FaDu	EC₅₀	12.1 μM Compound: 17; CAPE	Cytotoxicity against human FADU cells measured after 96 hrs by SRB assay Cytotoxicity against human FADU cells measured after 96 hrs by SRB assay	[PMID: 31158743]
HeLa	IC₅₀	0.068 μg/mL Compound: 9	Antiallergic activity in Ca(2+)-stimulated differentiated human HeLa cells assessed as inhibition of cys-leukotriene release after 6 days by ELISA Antiallergic activity in Ca(2+)-stimulated differentiated human HeLa cells assessed as inhibition of cys-leukotriene release after 6 days by ELISA	[PMID: 19942440]
HeLa	EC₅₀	2.36 μM Compound: 14	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 12027739]
HeLa	IC₅₀	33 μM Compound: CAPE	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 27979593]
HeLa	IC₅₀	37.98 μM Compound: I-18	Antitumor activity against human HeLa cells assessed as inhibition of cell growth by MTT assay Antitumor activity against human HeLa cells assessed as inhibition of cell growth by MTT assay	[PMID: 25160837]
HeLa	IC₅₀	8.8 μM Compound: 1, CAPE	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 20673727]
HepG2	IC₅₀	40.87 μM Compound: I-18	Antitumor activity against human HepG2 cells assessed as inhibition of cell growth by MTT assay Antitumor activity against human HepG2 cells assessed as inhibition of cell growth by MTT assay	[PMID: 25160837]
HL-60	IC₅₀	16.65 μM Compound: I-18	Antitumor activity against human HL60 cells assessed as inhibition of cell growth by MTT assay Antitumor activity against human HL60 cells assessed as inhibition of cell growth by MTT assay	[PMID: 25160837]
HL-60	IC₅₀	9.8 μM Compound: 1, CAPE	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 20673727]
HT-1080	EC₅₀	9.5 μM Compound: 14	Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 12027739]
HT-29	EC₅₀	> 30 μM Compound: 17; CAPE	Cytotoxicity against human HT-29 cells measured after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells measured after 96 hrs by SRB assay	[PMID: 31158743]
HUVEC	EC₅₀	8 μM Compound: CAPE	Cytoprotective activity against H2O2-induced oxidative stress in HUVEC cells after 18 hrs by Cell-Titer Blue assay Cytoprotective activity against H2O2-induced oxidative stress in HUVEC cells after 18 hrs by Cell-Titer Blue assay	[PMID: 20598894]
IMR-32	IC₅₀	5 μM Compound: 2; CAPE	Cytotoxicity against human IMR-32 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human IMR-32 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 33210536]
J774.1	IC₅₀	4.8 μM Compound: CAPE	Inhibition of LPS-induced NO production in mouse J774.1 cells after 24 hrs by Griess reagent assay Inhibition of LPS-induced NO production in mouse J774.1 cells after 24 hrs by Griess reagent assay	[PMID: 15974608]
JJN-3	IC₅₀	30 μM Compound: 2; CAPE	Growth inhibition of human JJN-3 cells after 48 hrs by PrestoBlue cell viability assay Growth inhibition of human JJN-3 cells after 48 hrs by PrestoBlue cell viability assay	[PMID: 33210536]
K562	IC₅₀	46 μM Compound: 1, CAPE	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 20673727]
KB	IC₅₀	45.2 μM Compound: 1, CAPE	Cytotoxicity against human KB cells after 72 hrs by MTT assay Cytotoxicity against human KB cells after 72 hrs by MTT assay	[PMID: 20673727]
KMM-1	IC₅₀	37.5 μM Compound: 2; CAPE	Growth inhibition of human KMM-1 cells after 48 hrs by PrestoBlue cell viability assay Growth inhibition of human KMM-1 cells after 48 hrs by PrestoBlue cell viability assay	[PMID: 33210536]
LNCaP	IC₅₀	33.7 μM Compound: 2, CAPE	Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 24 hrs by WST-1 assay Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 24 hrs by WST-1 assay	[PMID: 24080105]
LNCaP	IC₅₀	6.2 μM Compound: 2, CAPE	Antiandrogenic activity in human LNCAP cells assessed as reduction in DHT-stimulated PSA release after 24 hrs by ELISA Antiandrogenic activity in human LNCAP cells assessed as reduction in DHT-stimulated PSA release after 24 hrs by ELISA	[PMID: 24080105]
LS174T	IC₅₀	9.9 μM Compound: 1, CAPE	Cytotoxicity against human LS 174T cells after 72 hrs by MTT assay Cytotoxicity against human LS 174T cells after 72 hrs by MTT assay	[PMID: 20673727]
Macrophage	IC₅₀	15 μM Compound: CAPE	Inhibition of LPS-induced NO production in ddY mouse macrophages after 20 hrs by Griess reagent assay Inhibition of LPS-induced NO production in ddY mouse macrophages after 20 hrs by Griess reagent assay	[PMID: 15270564]
MCF7	EC₅₀	12.1 μM Compound: 17; CAPE	Cytotoxicity against human MCF7 cells measured after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells measured after 96 hrs by SRB assay	[PMID: 31158743]
MCF7	IC₅₀	26.7 μM Compound: III-19	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 18952420]
MCF7	IC₅₀	28.8 μM Compound: CAPE	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 27979593]
NIH3T3	EC₅₀	21.4 μM Compound: 17; CAPE	Cytotoxicity against mouse NIH/3T3 cells measured after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells measured after 96 hrs by SRB assay	[PMID: 31158743]
PC-12	IC₅₀	2 μM Compound: CAPE	Neuroprotection activity in rat PC12 cells assessed as reduction in H2O2-induced cell death preincubated for 3 hrs followed by H2O2 addition and measured after 3 hrs by MTS assay Neuroprotection activity in rat PC12 cells assessed as reduction in H2O2-induced cell death preincubated for 3 hrs followed by H2O2 addition and measured after 3 hrs by MTS assay	[PMID: 30928712]
PC-3	IC₅₀	10.15 μM Compound: CAPE	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 26638042]
PC-3	IC₅₀	51.4 μM Compound: 2, CAPE	Antiproliferative activity against human PC3 cells after 72 hrs by trypan blue assay Antiproliferative activity against human PC3 cells after 72 hrs by trypan blue assay	[PMID: 24080105]
PC-3	IC₅₀	91 μM Compound: 1, CAPE	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 20673727]
Peritoneal macrophage	IC₅₀	4.31 μM Compound: 5; CAPE	Anti-inflammatory activity in ICR mouse peritoneal macrophages assessed inhibition of LPS-induced TNF-alpha production preincubated for 30 to 60 mins followed by LPS stimulation measured after 24 hrs by ELISA Anti-inflammatory activity in ICR mouse peritoneal macrophages assessed inhibition of LPS-induced TNF-alpha production preincubated for 30 to 60 mins followed by LPS stimulation measured after 24 hrs by ELISA	[PMID: 29202400]
Peritoneal macrophage cell	IC₅₀	11 μM Compound: CAPE	Hepatoprotective activity in ddY mouse peritoneal macrophages assessed as inhibition of LPS-induced nitric oxide production after 20 hrs by Griess method relative to untreated control Hepatoprotective activity in ddY mouse peritoneal macrophages assessed as inhibition of LPS-induced nitric oxide production after 20 hrs by Griess method relative to untreated control	[PMID: 19775895]
RAW264.7	EC₅₀	0.193 μM Compound: Table 1, R23C1	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells assessed as nitrite accumulation administered 1 hr before LPS challenge and measured after 24 hrs by Griess reagent assay Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells assessed as nitrite accumulation administered 1 hr before LPS challenge and measured after 24 hrs by Griess reagent assay	[PMID: 18667320]
RAW264.7	IC₅₀	3.8 μM Compound: CAPE	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 10 mins prior to LPS-challenge measured after 18 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 10 mins prior to LPS-challenge measured after 18 hrs by Griess method	[PMID: 22831798]
RAW264.7	EC₅₀	4.518 μM Compound: Table 1, R23C1	Cytotoxicity against mouse RAW264.7 cells assessed as cell survival after 24 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as cell survival after 24 hrs by MTT assay	[PMID: 18667320]
RAW264.7	IC₅₀	9.3 μM Compound: CAPE	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method	[PMID: 28561586]
RCC4	IC₅₀	14 μM Compound: 2; CAPE	Cytotoxicity against VHL-deficient human RCC4 cells assessed as reduction in cell viability incubated for 4 days by XTT assay Cytotoxicity against VHL-deficient human RCC4 cells assessed as reduction in cell viability incubated for 4 days by XTT assay	[PMID: 31260889]
RCC4/VHL	IC₅₀	29.1 μM Compound: 2; CAPE	Cytotoxicity against VHL-positive human RCC4/VHL cells assessed as reduction in cell viability incubated for 4 days by XTT assay Cytotoxicity against VHL-positive human RCC4/VHL cells assessed as reduction in cell viability incubated for 4 days by XTT assay	[PMID: 31260889]
SGC-7901	IC₅₀	14.26 μM Compound: I-18	Antitumor activity against human SGC7901 cells assessed as inhibition of cell growth by MTT assay Antitumor activity against human SGC7901 cells assessed as inhibition of cell growth by MTT assay	[PMID: 25160837]
SiHa	IC₅₀	66.92 μM Compound: I-18	Antitumor activity against human SiHa cells assessed as inhibition of cell growth by MTT assay Antitumor activity against human SiHa cells assessed as inhibition of cell growth by MTT assay	[PMID: 25160837]
SW-1736	EC₅₀	4.7 μM Compound: 17; CAPE	Cytotoxicity against human SW1736 cells measured after 96 hrs by SRB assay Cytotoxicity against human SW1736 cells measured after 96 hrs by SRB assay	[PMID: 31158743]

体外研究
(In Vitro)

Caffeic acid phenethyl ester 是一种 NF-κB 抑制剂。CRPC 细胞系的细胞存活和增殖均受到 Caffeic acid phenethyl ester (CAPE) 剂量依赖性处理的显著抑制。Caffeic acid phenethyl ester 的生长抑制作用在处理后 24 小时内很明显，但抑制作用会随着时间的推移而累积。Caffeic acid phenethyl ester 处理 LNCaP 104-R1 细胞 24、48、72 和 96 h 的 IC₅₀ 分别为 64.0、30.5、20.5 和 18.0 μM。集落形成测定表明，用 10 μM Caffeic acid phenethyl ester 处理可使 LNCaP 104-R1 细胞的集落形成减少 90%，而用 20 μM Caffeic acid phenethyl ester 处理可完全阻止 LNCaP 104-R1 集落的形成。流式细胞术分析显示，在 Caffeic acid phenethyl ester 处理下，LNCaP 104-R1 细胞中 S 期和 G2/M 期细胞减少，但 G1 期细胞群增加。Caffeic acid phenethyl ester 显着降低脂肪酸合成酶 (FAS)、视网膜母细胞瘤蛋白 (Rb)、磷酸化 Rb Ser807/811、c-Myc、p70S6 激酶、磷酸化 p70S6 激酶 Thr421/Ser424、Skp2、p90RSK 和 NF-κB p65 的蛋白质水平^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

通过管饲法 (每天 10 mg/kg) 施用 Caffeic acid phenethyl ester (CAPE) 八周可使肿瘤体积减少 50%，这表明 Caffeic acid phenethyl ester 处理可延缓 LNCaP 104-R1 异种移植肿瘤的生长。Caffeic acid phenethyl ester 灌胃减缓了 LNCaP 104-R1 细胞的肿瘤生长，这与我们观察到的 Caffeic acid phenethyl ester 处理诱导细胞周期停滞但不诱导细胞凋亡一致^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

284.31

Formula

C₁₇H₁₆O₄

CAS 号

104594-70-9

性状

固体

颜色

White to off-white

中文名称

咖啡酸苯乙酯

结构分类

初始来源

动物

Propolis

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

溶解性数据

细胞实验：

DMSO 中的溶解度 : 100 mg/mL (351.73 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

H₂O 中的溶解度 : < 0.1 mg/mL (insoluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.5173 mL	17.5864 mL	35.1729 mL
5 mM	0.7035 mL	3.5173 mL	7.0346 mL
10 mM	0.3517 mL	1.7586 mL	3.5173 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C储存时，请在1年内使用， -20°C储存时，请在6个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.79 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.79 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (8.79 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： 50% PEG300 50% Saline
Solubility: 20 mg/mL (70.35 mM); 澄清溶液; 超声助溶

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.96%

选择批次：

Data Sheet (647 KB) SDS (252 KB)

COA (189 KB) LCMS (265 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Lin HP, et al. Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1. Oncotarget. 2015 Mar 30;6(9):6684-707. [Content Brief]

Kinase Assay ^[1]	LNCaP 104-R1 cells are treated with 0, 10, 20, or 40 μM Caffeic acid phenethyl ester (CAPE) for 96 h. Three biological replicates of cells are lysed in SDS lysis buffer (240 mM Tris-acetate, 1% SDS, 1% glycerol, 5 mM EDTA pH 8.0) with DTT, protease inhibitors, and a cocktail of phosphatase inhibitors. Micro-Western Arrays are performed to measure protein expression and phosphorylation status modification^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Assay ^[1]	LNCaP 104-R1 cells are seeded at a density of 3×10³ cells per well in a 96-well plate. After 24 h, the cells are treated with increasing concentrations of Caffeic acid phenethyl ester (CAPE) for 96 h. Cell viability is assessed by an MTT (3,4,5-dimethylthiazol-2-yl)-2–5-diphenyltetrazolium bromide) assay. The amount of formazan is determined by measuring the absorbance at 560 nm using a plate reader. All results are normalized to the average of the control condition in each individual experiment. All experiments are repeated three times. Each time ten wells are utilized for each condition. The mean and standard deviation represent the results from all 30 wells in the three experiments^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	Male Balb/c nu/nu mice at age 6 to 8 weeks of age are injected subcutaneously in both flanks with 5×10⁵ LNCaP 104-R1 cells suspended in 0.5 mL of Matrigel and are injected subcutaneously into athymic mice to form tumors. After 14 weeks, the average tumor volume exceeds 150 mm³. The mice are then separated into control group and Caffeic acid phenethyl ester (CAPE) treatment group. Control group contains 6 mice and 8 tumors, while Caffeic acid phenethyl ester treatment group contains 6 mice and 9 tumors. Caffeic acid phenethyl ester (10 mg/kg/day in sesame oil) or vehicle (sesame oil) is administered by gavage starting from 14th week after cancer cell injection. Tumor volume and body weight of mice carrying 104-R1 xenografts are measured weekly using calipers and volume is calculated using the formula volume=length×width×height×0.52^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Lin HP, et al. Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1. Oncotarget. 2015 Mar 30;6(9):6684-707. [Content Brief]

Caffeic acid phenethyl ester 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.5173 mL	17.5864 mL	35.1729 mL	87.9322 mL
	5 mM	0.7035 mL	3.5173 mL	7.0346 mL	17.5864 mL
	10 mM	0.3517 mL	1.7586 mL	3.5173 mL	8.7932 mL
	15 mM	0.2345 mL	1.1724 mL	2.3449 mL	5.8621 mL
	20 mM	0.1759 mL	0.8793 mL	1.7586 mL	4.3966 mL
	25 mM	0.1407 mL	0.7035 mL	1.4069 mL	3.5173 mL
	30 mM	0.1172 mL	0.5862 mL	1.1724 mL	2.9311 mL
	40 mM	0.0879 mL	0.4397 mL	0.8793 mL	2.1983 mL
	50 mM	0.0703 mL	0.3517 mL	0.7035 mL	1.7586 mL
	60 mM	0.0586 mL	0.2931 mL	0.5862 mL	1.4655 mL
	80 mM	0.0440 mL	0.2198 mL	0.4397 mL	1.0992 mL
	100 mM	0.0352 mL	0.1759 mL	0.3517 mL	0.8793 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Caffeic acid phenethyl ester104594-70-9咖啡酸苯乙酯NF-κBApoptosisNuclear factor-κBNuclear factor-kappaBInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Caffeic acid phenethyl ester (Synonyms: 咖啡酸苯乙酯)

Customer Review

Other Forms of Caffeic acid phenethyl ester:

MCE 顾客使用本产品发表的 12 篇科研文献

Caffeic acid phenethyl ester 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 NF-κB 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Caffeic acid phenethyl ester 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Caffeic acid phenethyl ester (Synonyms: 咖啡酸苯乙酯)

Customer Review

Other Forms of Caffeic acid phenethyl ester:

Caffeic acid phenethyl ester 相关抗体

MCE 顾客使用本产品发表的 12 篇科研文献

Caffeic acid phenethyl ester 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 NF-κB 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

Caffeic acid phenethyl ester 相关抗体:

摩尔计算器

稀释计算器

Caffeic acid phenethyl ester 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z